Table 3 Responses in pazopanib combination trials.

From: Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors

Best response obtained

Number of patients

Stable disease

16

Progression of disease

23

Partial response

4

Intolerant to treatment

1

Back to article page